Clinical trial · Interventional
Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer
A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)
NCT02141919CI-TRIAL-00099723active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cancers | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic Ablative Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Stereotactic Ablative Radiation Therapy
- description
- Stereotactic Ablative Radiation Therapy (SABR)
- interventionNames
- Radiation: Stereotactic Ablative Radiation Therapy
Primary outcomes (1)
- measure
- Eliminate its growth and tumor viability.
- timeFrame
- 2 years
- description
- To evaluate if SABR to small renal tumors is able to eliminate its growth and viable tumor.
Secondary outcomes (5)
- measure
- Adverse events
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria * Age ≥ 18 years. * Renal mass ≤ 5cm * The treating renal mass must be ≤ 5cm. Other renal masses (cysts etc.) of any size will not make the subject ineligible * Biopsy proven Renal neoplasm * All histology of renal cancers are included including oncocytoma * Growth of renal mass \>2mm in radiographic scans must be demonstrated within a one year period. * Ability to understand and the willingness to sign a written informed consent. * Subject is able to undergo either an MRI or administration of contrast agent for CT * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Exclusion Criteria: * Subject has received any treatment for the treating renal mass; such as RFA or cyroablation. * If other renal masses received RFA or cryoablation or surgery, then these patients are eligible. * Subjects received previous abdominal radiation * Evidence of Metastatic Disease, unless disease-free for ≥ 3 years prior to registration, (non-melanomatous skin cancer and in-situ cancers are okay). * Female subjects who are pregnant or planning to become pregnant during the course of SABR.
References
Publications (0)
Data not yet available
No reference posted for this study.